Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Yale studying possible COVID-19 treatment

By Sean Whooley | August 3, 2020

COVID-19 coronavirus

[Photo by Fusion Medical Animation on Unsplash]

Yale School of Medicine and AI Therapeutics announced the launch of a multi-institutional clinical trial for a drug for treating COVID-19.

LAM-002A (apilimod) has a proven safety record and preliminary research has shown that it can block the cellular entry and trafficking of the SARS-CoV-2 virus that is causing COVID-19, according to a news release. Guilford, Conn.-based AI Therapeutics owns the intellectual property rights to the drug.

Enrollment has now begun for a Phase II trial for the drug’s use as a COVID-19 treatment, with the expectation of enrolling 142 newly diagnosed patients to test the safety and efficacy of the drug in reducing virus levels in infected individuals. Previous trials of more than 700 patients have shown LAM-002A to be safe in treating autoimmune diseases and follicular lymphoma, as well.

A study published in Nature that observed more than 13,000 existing drugs against two strains of the live SARS-CoV-2 virus found LAM-002A to be the most effective in combatting the virus, including in lung cells infected with the virus. Another study (published in CellI) independently showed that the drug could combat the virus in infections in human lung cells, too.

Should LAM-002A show effectiveness, the trial could be expanded to assess whether it would help prevent the development of the disease after exposure, particularly in high-risk populations, including within nursing homes, healthcare facilities and underserved communities, according to Yale professor of neurosurgery, genetics and neuroscience Murat Gunel, the chief scientific adviser to AI Therapeutics and someone who holds a financial interest in the company.

“LAM-002A holds promise to be a powerful new therapy for COVID-19 patients to prevent progression of disease, hopefully avoiding the need for hospitalization” Gunel said.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: AI Therapeutics, coronavirus, covid-19, Yale University
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE